Sara Bitam
Overview
Explore the profile of Sara Bitam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pranke I, Chevalier B, Premchandar A, Baatallah N, Tomaszewski K, Bitam S, et al.
Cell Mol Life Sci
. 2022 Aug;
79(9):503.
PMID: 36045259
Early recognition and enhanced degradation of misfolded proteins by the endoplasmic reticulum (ER) quality control and ER-associated degradation (ERAD) cause defective protein secretion and membrane targeting, as exemplified for Z-alpha-1-antitrypsin...
2.
Bitam S, Elbahnsi A, Creste G, Pranke I, Chevalier B, Berhal F, et al.
Sci Rep
. 2021 Sep;
11(1):18709.
PMID: 34526640
No abstract available.
3.
Bitam S, Elbahnsi A, Creste G, Pranke I, Chevalier B, Berhal F, et al.
Sci Rep
. 2021 Mar;
11(1):6842.
PMID: 33767236
C407 is a compound that corrects the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein carrying the p.Phe508del (F508del) mutation. We investigated the corrector effect of c407 and its derivatives on...
4.
Bignon Y, Sakhi I, Bitam S, Bakouh N, Keck M, Frachon N, et al.
Hum Mutat
. 2019 Dec;
41(4):774-785.
PMID: 31803959
Pathological missense mutations in CLCNKB gene give a wide spectrum of clinical phenotypes in Bartter syndrome type III patients. Molecular analysis of the mutated ClC-Kb channels can be helpful to...
5.
Baatallah N, Bitam S, Martin N, Servel N, Costes B, Mekki C, et al.
Hum Mutat
. 2017 Dec;
39(4):506-514.
PMID: 29271547
Molecules correcting the trafficking (correctors) and gating defects (potentiators) of the cystic fibrosis causing mutation c.1521_1523delCTT (p.Phe508del) begin to be a useful treatment for CF patients bearing p.Phe508del. This mutation...
6.
Louet M, Bitam S, Bakouh N, Bignon Y, Planelles G, Lagorce D, et al.
Sci Rep
. 2017 Aug;
7(1):7249.
PMID: 28775266
The human ClC-Kb channel plays a key role in exporting chloride ions from the cytosol and is known to be involved in Bartter syndrome type 3 when its permeation capacity...
7.
Faure G, Bakouh N, Lourdel S, Odolczyk N, Premchandar A, Servel N, et al.
J Mol Biol
. 2016 Jun;
428(14):2898-915.
PMID: 27241308
Deletion of Phe508 in the nucleotide binding domain (∆F508-NBD1) of the cystic fibrosis transmembrane regulator (CFTR; a cyclic AMP-regulated chloride channel) is the most frequent mutation associated with cystic fibrosis....
8.
Bitam S, Pranke I, Hollenhorst M, Servel N, Moquereau C, Tondelier D, et al.
F1000Res
. 2015 Nov;
4:218.
PMID: 26594334
Cystic fibrosis (CF) is a multifactorial disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene ( CFTR), which encodes a cAMP-dependent Cl (-) channel. The most frequent...
9.
Odolczyk N, Fritsch J, Norez C, Servel N, da Cunha M, Bitam S, et al.
EMBO Mol Med
. 2013 Aug;
5(10):1484-501.
PMID: 23982976
The deletion of Phe508 (ΔF508) in the first nucleotide binding domain (NBD1) of CFTR is the most common mutation associated with cystic fibrosis. The ΔF508-CFTR mutant is recognized as improperly...
10.
Colas J, Faure G, Saussereau E, Trudel S, Rabeh W, Bitam S, et al.
Hum Mol Genet
. 2011 Nov;
21(3):623-34.
PMID: 22038833
We have previously reported an increased expression of cytokeratins 8/18 (K8/K18) in cells expressing the F508del mutation of cystic fibrosis transmembrane conductance regulator (CFTR). This is associated with increased colocalization...